International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia by Ondrej Hrusak, Valerie de Haas, Jitka Stancikova,

Slides:

Advertisements

Similar presentations

Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.

Advertisements

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide Asha Johny, Kevin W.

Maury S et al. Proc ASH 2015;Abstract 1.

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

by Timothy P. Hughes, and David M. Ross

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

CD25 expression is associated with unfavorable clinical outcome.

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.

Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

How I treat elderly patients with myeloma

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report Ivana N.

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first.

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Gastrointestinal Acute Graft-versus-Host Disease in Children: Histology for Diagnosis, Mesenchymal Stromal Cells for Treatment, and Biomarkers for Prediction.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study by Andreas K. Øvlisen, Anders Oest,

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors by Teal S. Hallstrand,

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Volume 19, Issue 2, Pages (February 2011)

Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker Manuela Giachelia, Valentina Bozzoli,

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced.

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL by Lina Hamadeh, Amir Enshaei, Claire Schwab,

Volume 13, Issue 9, Pages (September 2012)

Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Treatment versus Transplant for Challenging Hematologic Disorders

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

How I treat refractory and early relapsed acute myeloid leukemia

Volume 24, Issue 9, Pages (September 2016)

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

by Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H

by Jan J. Cornelissen, and Didier Blaise

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M

Presentation transcript:

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia by Ondrej Hrusak, Valerie de Haas, Jitka Stancikova, Barbora Vakrmanova, Iveta Janotova, Ester Mejstrikova, Vaclav Capek, Jan Trka, Marketa Zaliova, Ales Luks, Kirsten Bleckmann, Anja Möricke, Julie Irving, Benigna Konatkowska, Thomas B. Alexander, Hiroto Inaba, Kjeld Schmiegelow, Simone Stokley, Zuzana Zemanova, Anthony V. Moorman, Jorge Gabriel Rossi, Maria Sara Felice, Luciano Dalla-Pozza, Jessa Morales, Michael Dworzak, Barbara Buldini, Giuseppe Basso, Myriam Campbell, Maria Elena Cabrera, Neda Marinov, Sarah Elitzur, Shai Izraeli, Drorit Luria, Tamar Feuerstein, Alexandra Kolenova, Peter Svec, Olena Kreminska, Karen R. Rabin, Sophia Polychronopoulou, Elaine da Costa, Hanne Vibeke Marquart, Antonis Kattamis, Richard Ratei, Dirk Reinhardt, John K. Choi, Martin Schrappe, and Jan Stary Blood Volume 132(3):264-276 July 19, 2018 ©2018 by American Society of Hematology

Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Flowchart. Flowchart. Rectangles contain selection criteria in each step, followed by the number of patients in parentheses. Tables or figures mentioned next to each rectangle depict all patients from the respective node unless a selection is specified in a footnote. Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Outcome of patients with ALAL by the primary type of treatment. Outcome of patients with ALAL by the primary type of treatment. (A) EFS. (B) Overall survival. A log-rank (Mantel-Cox) statistical test was used. Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Outcome of patients with ALAL on different treatment types. Outcome of patients with ALAL on different treatment types. Single-population ALAL vs bilineal ALAL. (A) EFS. (B) Overall survival. A log-rank (Mantel-Cox) statistical test was used. Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Outcome of children with CD19+ ALAL and CD19−ALAL with other lymphoid-specific antigens by the type of primary therapy. Outcome of children with CD19+ALAL and CD19−ALAL with other lymphoid-specific antigens by the type of primary therapy. Patients without ETV6/RUNX1, RUNX1/RUNX1T1, PML/RARA, or BCR/ABL1 gene fusions. A log-rank (Mantel-Cox) statistical test was used. (A) EFS of CD19+ ALAL. (B) EFS of CD 19− ALAL with other lymphoid-specific antigens. (C) Overall survival of CD19+ patients. (D) Overall survival of CD19− ALAL with other lymphoid-specific antigens. Other lymphoid-specific antigens are listed in “Results.” Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Outcome of ALAL patients transplanted in the first complete remission compared with other patients. Outcome of ALAL patients transplanted in the first complete remission compared with other patients. In each type of primary treatment, events occurring prior to the median time to transplant were neglected. A log-rank (Mantel-Cox) statistical test was used. (A) ALL treatment type EFS. (B) Combined-type treatment EFS. (C) EFS. (D) ALL treatment type overall survival. (E) Combined-type treatment overall survival. (F) AML treatment type overall survival. Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Outcome of ALAL patients in relation to their response to prednisone. Outcome of ALAL patients in relation to their response to prednisone. (A) CD19+ EFS. (B) CD19− EFS. (C) CD19+ overall survival. (D) CD19− overall survival. A log-rank (Mantel-Cox) statistical test was used. Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology

Treatment recommendation algorithm. Treatment recommendation algorithm. After each decision node, the number (percentage) of patients who still remain to be categorized is given. Note that the algorithm shows a recommendation to be tested prospectively and does not refer to the way in which patients in this study were treated. Numbers (percentages) include all 233 patients in the study with confirmed inclusion criteria. Neg, negative; pos, positive (or partly positive). TKI, tyrosine kinase inhibitor. Ondrej Hrusak et al. Blood 2018;132:264-276 ©2018 by American Society of Hematology